New Hemp Discoveries

Whether you are a new Hemp enthusiast or a seasoned user, the discoveries in Cannabinoid research can benefit you. Some of the latest studies suggest Cannabinoid acids can help fight inflammatory bowel disease and psoriasis.

Cannabinoid acids bind to SARS-CoV-2 spike protein
Using a special screening method, scientists at Oregon State University have discovered cannabinoid acids in hemp that bind to SARS-CoV-2 spike protein. These compounds are believed to block the virus from entering human cells, preventing infection and shortening the length of an infection.

The SARS-CoV-2 coronavirus is an RNA-based coronavirus that features four main structural proteins and numerous “accessory” proteins. It also features crown-like protrusions on its outer surface. The virus is visualized with an anti-ds-RNA antibody.

The coronavirus has four RNA strands that encode its structural proteins and a spike protein used as a drug target in COVID-19 vaccines. Several compounds that block the interaction between virus and receptor have been used to treat HIV-1 and hepatitis.

In the study, van Breemen’s laboratory developed a special screening method that identified two compounds. The researchers then tested their antiviral activity on human endothelial cells. During the test, they found that CBD and cannabigerol acid (CBGA) both inhibited the expression of SARS-CoV-2 spike protein in the host cell.

The compounds also blocked the entry of live SARS-CoV-2 virus into the cell. This step is critical to the pathogen’s ability to infect human cells.

The researchers screened a variety of botanicals. The results showed that hemp compounds were equally effective against both the alpha and beta variants of the SARS-CoV-2 virus. The study was a collaboration between Oregon Health & Science University and Oregon State University. The research was published in the Journal of Natural Products.

The compounds exhibited a high affinity for the SARS-CoV-2 spike protein. This was confirmed by the researchers, who filtered out non-binding molecules and used UHPLC-MS and MagMASS to identify cannabinoid acids. They then released the cannabinoid acids into an organic solvent.

Cannabinoid acids prevent COVID-19 from entering human cells.
Using hemp as the basis for a study on the effectiveness of cannabinoid acids in preventing COVID-19, researchers at Oregon State University found that these compounds blocked the virus from entering human cells. Cannabinoid acids are allosteric ligands that bind to a spike protein on the coronavirus. In this process, they inhibit the ACE-2 receptors in the outer membrane of endothelial cells, blocking the vital step in the virus’s infection process.

These compounds may also be effective in preventing the virus from infecting healthy human cells, shortening infections, and reducing the risk of complications. The results of this study were published in the Journal of Natural Products.

The study also included scientists from Oregon Health & Science University. These scientists tested some botanicals, including hops, wild yam, and three species of licorice. They found that hemp products had the highest affinity for spike protein binding. These compounds were then tested against a pseudovirus expressing SARS-CoV-2 spike protein.

CBD was effective at inhibiting the expression of SARS-CoV-2 spike protein in host cells after two hours. In the presence of antibodies to the spike protein, it was effective in blocking viral entry. However, more testing is necessary to determine whether the compound is effective against live viruses.

The study also found that hemp products were effective against variants of SARS-CoV-2, a coronavirus that causes severe acute respiratory syndrome. These variants evade antibodies against the early lineage SARS-CoV-2, which is why current vaccination strategies depend on the spike protein as a viral antigen.

Van Breemen believes combining vaccination and treatment with CBDA and CBGA will make the environment more challenging for SARS-CoV-2.

Cannabinoid acids prevent the entry of SARS-CoV-2 into human cells
During a study at Oregon State University, researchers found that hemp compounds inhibited the entry of the SARS-CoV-2 virus into human cells. These compounds bind to the virus’s spike protein, a crucial step in the viral infection process.

Scientists identified hemp compounds using a screening technique that used affinity-selection selection mass spectrometry. The drug target was placed in a ligand-based incubation and filtered out non-binding molecules in this screening method. These compounds were then isolated and identified.

Scientists were able to identify the cannabinoid acids found in hemp. They found that these acids are orthosteric ligands with micromolar affinity to the SARS-CoV-2 spike protein. Several hemp varietals contain cannabinoid acids. They also found that these compounds are non-psychoactive and have a good safety profile in humans.

Cannabinoid acids also prevent the COVID-19 virus from entering human cells. In addition to hemp, the researchers tested the ability of red clover, wild yam, hops, and three species of licorice to prevent SARS-CoV-2 from infecting human cells. These botanicals all have a similar structure to hemp.

These findings support the use of cannabinoid acids as a potential therapy for SARS-CoV-2 infections. They have a high safety profile in humans and are available in many extracts. These compounds can be taken orally and have a history of safe use in humans.

Researchers believe combining vaccination and cannabinoid treatment will make viral survival difficult. This would be particularly beneficial against resistant strains.

Cannabinoid acids found in hemp have a long history of safe human use. They have been used to treat HIV-1 and hepatitis. Several other viral infections have benefitted from compounds that block the interaction between the virus and its receptors.

Cannabinoid acids are effective against psoriasis.
Despite the stigma associated with psoriasis, many patients have found relief using CBD products. These natural ingredients can help relieve inflammation, itching, and pain.

The endocannabinoid system is a complex biological system, and ongoing medical research is teasing out the mechanisms involved. Cannabinoids are a class of pharmacologically active compounds produced by the cannabis plant. They act as anti-inflammatory agents and may help regulate the immune and nervous systems.

Although more research is needed, using cannabinoids in topical products is effective for several inflammatory skin conditions. The compounds can also affect the growth of skin cells, which can lead to a reduction in the buildup of plaques.

A large-scale clinical study is necessary to evaluate CBD’s effects on skin inflammation fully. Topical treatment is usually effective for 8 to 12 hours.

There are many types of CBD-based products that can be used on the skin. Some contain various natural ingredients, while others are based on CBD alone. These products can be applied directly to the skin or can be ingested.

A CBD-based product can help improve the skin’s overall elasticity, hydration, and quality of life. Some studies have also indicated that it can reduce psoriatic plaques and restore the skin’s inflammatory balance.

The use of cannabinoids to treat psoriasis is promising, and more research is needed to determine its long-term effects. However, it is important to note that scientific evidence does not yet exist for the safety of CBD, and some people experience unpleasant side effects. Those with heightened irritation should seek professional medical advice.

The use of natural products in dermatology is considered important due to their ecological benefits, the potential for therapeutic benefit, and the burden on healthcare systems. Several topical products are now based on cannabinoids endorsed by the National Psoriasis Foundation. These products are free of heavy metals, mold, and pesticides and include a stated dosage.

Cannabinoid acids are effective against inflammatory bowel disease.
Several pre-clinical studies suggest that cannabinoid acids in hemp are effective against inflammatory bowel diseases (IBD). They have anti-inflammatory, analgesic, and antioxidant properties and may help reduce inflammation and improve pain and quality of life in IBD. The endocannabinoid system, composed of various endogenous receptors, regulates the gut microbiota, mucosal permeability, and hemostasis. It also has a role in intercellular lipid signaling.

Several cannabinoid agonists, including D9-tetrahydrocannabivarin (THC), enzymatically-produced cannabinoids, and phytocannabinoids. The latter has been characterized in vitro and mice. In the human colon, palmitoylethanolamide has been shown to have anti-inflammatory effects. However, the characterization of other cannabinoids is still limited.

Using computational modeling, phytocannabinoids were found to be novel dual PPARa/g agonists. These compounds are terpenoids that have potent anti-inflammatory activity. Their activity was confirmed in three cell lines. The PPAR family is a group of nuclear receptor transcription factors that control inflammation, hepatic metabolic functions, and gene transcription. They accept a wide range of ligands. The PPAR family includes PPARg, PPARa, and PPARdelta.

These receptors are well-known for their anti-inflammatory properties. They also have anti-nausea and analgesic properties. They suppress ascending enteric reflex, propulsive peristalsis, and gastroesophageal reflux. These activities can benefit IBD by decreasing oxygen-free radicals in the intestinal epithelium.

To examine the pharmacokinetics of cannabinoid acids in mice, a mouse brain model was used. Cannabinoid concentrations were measured at five-time points: 15 minutes, 45 minutes, two hours, eight hours, and 12 hours. They were averaged at each time point. To calculate the elimination rate constants, a linear regression of the terminal component of the concentration-time curve was performed.

Several cannabinoid acids were found to be rapidly absorbed and metabolized. They had relatively short half-lives and 15 to 45 minutes plasma values.